ASP Isotopes (ASPI) Emerging Growth Conference 97 summary
Event summary combining transcript, slides, and related documents.
Emerging Growth Conference 97 summary
28 Oct, 2026Business strategy and technology
Four verticals span nuclear medicine, electronic gases, medical isotopes and nuclear energy; Quantum Leap Energy is expected to spin out and be separately listed on Nasdaq.
South African plants for carbon-14, silicon-28 and ytterbium-176 are built; silicon-28 is operational and progressing toward its first batch shipment.
ASP and laser-based quantum enrichment processes target isotope supply gaps; the speaker cited zero U.S. domestic production for the isotopes under consideration and Russia as a major supplier.
Noble Africa began liquid helium production; first commercial isotope shipments are targeted before year-end, with helium shipments planned for December and January.
Nuclear medicine and radiopharmacies
PET Labs supplies tens of thousands of nuclear medicine doses annually in South Africa; NuMed and East Coast Nuclear Pharmacy operate in the U.S.
Focus is on higher-value cancer-treatment isotopes, including ytterbium-176 feedstock for lutetium-177 used in Novartis’ PLUVICTO; estimated future global ytterbium and gadolinium market is $100m.
Global nuclear medicine market estimated at $33bn, radiopharmaceuticals at $13.5bn and commercial radiopharmacy at $6bn; market growth forecast at 8% from 2026 to 2031.
Plan to acquire and upgrade radiopharmacies with advanced production capabilities; target is about 10 locations in five years and 30 in 10 years.
Alpa Theranostics pipeline
Alpa’s VHH nanobody platform pairs diagnostic and therapeutic radioisotopes; first candidates are expected to enter patients later in 2026, with Phase I data expected in 2027.
Three assets are planned to enter clinical development within six to nine months; initial focus includes triple-negative breast cancer and osteosarcoma.
Phase I trials are planned in South Africa, with a first U.S. IND filing targeted for 2027; management said the South African path from concept to IND could take about two years.
Latest events from ASP Isotopes
- Revenue grew, but losses and Renergen debt risks remain substantial.ASPI
Q3 2026 - Proprietary enrichment tech, global expansion, and strong financials drive $300–$700M 2031 EBITDA target.ASPI
CMD 2026 - Commercial production of isotopes and helium begins, targeting global supply gaps and strong growth.ASPI
Emerging Growth Conference - Quarterly revenue grew to $5.1M, net loss narrowed, and Renergen acquisition expanded operations.ASPI
Q2 2026 - Vertically integrated isotope and helium producer targets global expansion and strong financial growth.ASPI
Canaccord Genuity's 46th Annual Growth Conference - Phase I helium shipments begin September, with major expansion and strong contracts driving growth.ASPI
Investor update - Advancing isotope enrichment for semiconductors, medicine, and energy with 2026 milestones.ASPI
Corporate presentation - Expanding isotope enrichment and supply to critical markets with strong growth targets.ASPI
Corporate presentation - Commercial production ramped up across three plants, with strong cash reserves and growth outlook.ASPI
Q4 2024